This trial is testing a new treatment for pancreatic cancer in patients with an inherited BRCA1 or BRCA2 mutation. The treatment involves a combination of drugs given through an IV, with the goal of determining if it is safe.
11 Primary · 4 Secondary · Reporting Duration: Within 48 hours of vitamin C treatment
Experimental Treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: Autologous Hematopoietic Stem Cells · No Placebo Group · Phase 1
Age 18 - 70 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Kentucky | 100.0% |
65+ | 100.0% |
Massachusetts General Hospital | 100.0% |
Met criteria | 100.0% |
100.0% | |